There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.
Compare INCY Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Incyte
Drugmakers can be excellent long-term holdings.
Incyte is betting bigger on ruxolitinib to bring back growth.
Several products contributed to the biotech's solid Q4 growth.
Investors should take notice of this four-way competition.
Incyte might finally be convincing Wall Street that its pipeline is the real deal.
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Is the biotech company worth its rich valuation metrics?
Both diseases involve an overactive immune system.